Contributions
Abstract: PB1460
Type: Publication Only
Session title: Aggressive Non-Hodgkin lymphoma - Clinical
Background
Background: Peripheral T-cell lymphomas (PTCLs) are an aggressive and heterogeneous group of lymphomas with a T-cell origin. They are a rare entities, accounting for 10-15% of Non- Hodgkin lymphomas. The disease is generally incurable if refractory in the absence of transplantation and treatment is aimed at prolonging life and reducing disease-related symptoms. Belinostat is a histone deacetylate inhibitor that was granted accelerated approval by the US Food and Drug Administration on July 3, 2014, for the treatment of patients with relapsed or refractory PTCLs. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.
Aims
Case report.
Methods
Case Summary: 60 year old male patient with PTCL not otherwise specified (PTCL-NOS), Ann Arbor stage IVE B, was being treated with four cycles of chemotherapy with CHOEP-21; he achieved a partial remission and a complete remission of disease after completing six cycles CHOEP-21. About 7 months after the end of treatment, he achivied a first relapse. The patient was treated with three courses of GemOX obtained a stable disease. A third line chemotherapy regimen with three cycles of DHAP protocol did not result in lymphoma remission. Subsequent treatment with Belinostat. After three cycles of belinostat, the patient achieved a partial response. After 6 months of belinostat therapy (8 cycles), the patient has maintained a PR. Belinostat therapy was well tolerated for all eight cycles with mild hematological and no hematological toxicities without any toxicity more than CTC grade 2. Belinostat therapy the patient in PR refused to continue the treatment. Two months later we observed a progression of disease and died.
Results
Monotherapy with belinostat has efficacy in Peripheral T-cell lymphomas.
Conclusion
Discussion: monotherapy with belinostat has comparable efficacy to other agents used in this setting and it is well tolerated in regard to hematologic events, but there is limited data on patient-reported outcomes, reduction in disease-related symptoms, or quality of life.
Keyword(s): Histone acetylation, Lymphoma therapy, Peripheral T-cell lymphoma
Abstract: PB1460
Type: Publication Only
Session title: Aggressive Non-Hodgkin lymphoma - Clinical
Background
Background: Peripheral T-cell lymphomas (PTCLs) are an aggressive and heterogeneous group of lymphomas with a T-cell origin. They are a rare entities, accounting for 10-15% of Non- Hodgkin lymphomas. The disease is generally incurable if refractory in the absence of transplantation and treatment is aimed at prolonging life and reducing disease-related symptoms. Belinostat is a histone deacetylate inhibitor that was granted accelerated approval by the US Food and Drug Administration on July 3, 2014, for the treatment of patients with relapsed or refractory PTCLs. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.
Aims
Case report.
Methods
Case Summary: 60 year old male patient with PTCL not otherwise specified (PTCL-NOS), Ann Arbor stage IVE B, was being treated with four cycles of chemotherapy with CHOEP-21; he achieved a partial remission and a complete remission of disease after completing six cycles CHOEP-21. About 7 months after the end of treatment, he achivied a first relapse. The patient was treated with three courses of GemOX obtained a stable disease. A third line chemotherapy regimen with three cycles of DHAP protocol did not result in lymphoma remission. Subsequent treatment with Belinostat. After three cycles of belinostat, the patient achieved a partial response. After 6 months of belinostat therapy (8 cycles), the patient has maintained a PR. Belinostat therapy was well tolerated for all eight cycles with mild hematological and no hematological toxicities without any toxicity more than CTC grade 2. Belinostat therapy the patient in PR refused to continue the treatment. Two months later we observed a progression of disease and died.
Results
Monotherapy with belinostat has efficacy in Peripheral T-cell lymphomas.
Conclusion
Discussion: monotherapy with belinostat has comparable efficacy to other agents used in this setting and it is well tolerated in regard to hematologic events, but there is limited data on patient-reported outcomes, reduction in disease-related symptoms, or quality of life.
Keyword(s): Histone acetylation, Lymphoma therapy, Peripheral T-cell lymphoma